The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Research Report 2025
Synopsis
Neuromyelitis optica (NMO), also known as Devic's disease, is a rare condition where the immune system damages the spinal cord and the nerves of the eyes (optic nerves).NMO can affect anyone at any age, but it's more common in women than men.
The global Neuromyelitis Optica Spectrum Disorders (NMOSD) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Neuromyelitis Optica Spectrum Disorders (NMOSD) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Neuromyelitis Optica Spectrum Disorders (NMOSD) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Neuromyelitis Optica Spectrum Disorders (NMOSD) in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Neuromyelitis Optica Spectrum Disorders (NMOSD) include Roche, Pfizer, Fresenius, Teva, Sandoz, Intas, Nang Kuang Pharmaceutical, Tianjin King York and Baxter, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Neuromyelitis Optica Spectrum Disorders (NMOSD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuromyelitis Optica Spectrum Disorders (NMOSD).
Report Scope
The Neuromyelitis Optica Spectrum Disorders (NMOSD) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neuromyelitis Optica Spectrum Disorders (NMOSD) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neuromyelitis Optica Spectrum Disorders (NMOSD) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Pfizer
Fresenius
Teva
Sandoz
Intas
Nang Kuang Pharmaceutical
Tianjin King York
Baxter
CSL
Grifols
Octapharma
Segment by Type
Relapsing Form
Monophasic Form
Segment by Application
Hospital
Clinic
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neuromyelitis Optica Spectrum Disorders (NMOSD) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Neuromyelitis optica (NMO), also known as Devic's disease, is a rare condition where the immune system damages the spinal cord and the nerves of the eyes (optic nerves).NMO can affect anyone at any age, but it's more common in women than men.
The global Neuromyelitis Optica Spectrum Disorders (NMOSD) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Neuromyelitis Optica Spectrum Disorders (NMOSD) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Neuromyelitis Optica Spectrum Disorders (NMOSD) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Neuromyelitis Optica Spectrum Disorders (NMOSD) in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Neuromyelitis Optica Spectrum Disorders (NMOSD) include Roche, Pfizer, Fresenius, Teva, Sandoz, Intas, Nang Kuang Pharmaceutical, Tianjin King York and Baxter, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Neuromyelitis Optica Spectrum Disorders (NMOSD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuromyelitis Optica Spectrum Disorders (NMOSD).
Report Scope
The Neuromyelitis Optica Spectrum Disorders (NMOSD) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neuromyelitis Optica Spectrum Disorders (NMOSD) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neuromyelitis Optica Spectrum Disorders (NMOSD) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Pfizer
Fresenius
Teva
Sandoz
Intas
Nang Kuang Pharmaceutical
Tianjin King York
Baxter
CSL
Grifols
Octapharma
Segment by Type
Relapsing Form
Monophasic Form
Segment by Application
Hospital
Clinic
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neuromyelitis Optica Spectrum Disorders (NMOSD) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Relapsing Form
1.2.3 Monophasic Form
1.3 Market by Application
1.3.1 Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Perspective (2019-2030)
2.2 Neuromyelitis Optica Spectrum Disorders (NMOSD) Growth Trends by Region
2.2.1 Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Neuromyelitis Optica Spectrum Disorders (NMOSD) Historic Market Size by Region (2019-2024)
2.2.3 Neuromyelitis Optica Spectrum Disorders (NMOSD) Forecasted Market Size by Region (2025-2030)
2.3 Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Dynamics
2.3.1 Neuromyelitis Optica Spectrum Disorders (NMOSD) Industry Trends
2.3.2 Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Drivers
2.3.3 Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Challenges
2.3.4 Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neuromyelitis Optica Spectrum Disorders (NMOSD) Players by Revenue
3.1.1 Global Top Neuromyelitis Optica Spectrum Disorders (NMOSD) Players by Revenue (2019-2024)
3.1.2 Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Revenue Market Share by Players (2019-2024)
3.2 Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neuromyelitis Optica Spectrum Disorders (NMOSD) Revenue
3.4 Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Concentration Ratio
3.4.1 Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuromyelitis Optica Spectrum Disorders (NMOSD) Revenue in 2023
3.5 Neuromyelitis Optica Spectrum Disorders (NMOSD) Key Players Head office and Area Served
3.6 Key Players Neuromyelitis Optica Spectrum Disorders (NMOSD) Product Solution and Service
3.7 Date of Enter into Neuromyelitis Optica Spectrum Disorders (NMOSD) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neuromyelitis Optica Spectrum Disorders (NMOSD) Breakdown Data by Type
4.1 Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Historic Market Size by Type (2019-2024)
4.2 Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Forecasted Market Size by Type (2025-2030)
5 Neuromyelitis Optica Spectrum Disorders (NMOSD) Breakdown Data by Application
5.1 Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Historic Market Size by Application (2019-2024)
5.2 Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size (2019-2030)
6.2 North America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2019-2024)
6.4 North America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size (2019-2030)
7.2 Europe Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2019-2024)
7.4 Europe Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size (2019-2030)
8.2 Asia-Pacific Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Region (2019-2024)
8.4 Asia-Pacific Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size (2019-2030)
9.2 Latin America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2019-2024)
9.4 Latin America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size (2019-2030)
10.2 Middle East & Africa Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2019-2024)
10.4 Middle East & Africa Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Neuromyelitis Optica Spectrum Disorders (NMOSD) Introduction
11.1.4 Roche Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Neuromyelitis Optica Spectrum Disorders (NMOSD) Introduction
11.2.4 Pfizer Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024)
11.2.5 Pfizer Recent Development
11.3 Fresenius
11.3.1 Fresenius Company Detail
11.3.2 Fresenius Business Overview
11.3.3 Fresenius Neuromyelitis Optica Spectrum Disorders (NMOSD) Introduction
11.3.4 Fresenius Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024)
11.3.5 Fresenius Recent Development
11.4 Teva
11.4.1 Teva Company Detail
11.4.2 Teva Business Overview
11.4.3 Teva Neuromyelitis Optica Spectrum Disorders (NMOSD) Introduction
11.4.4 Teva Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024)
11.4.5 Teva Recent Development
11.5 Sandoz
11.5.1 Sandoz Company Detail
11.5.2 Sandoz Business Overview
11.5.3 Sandoz Neuromyelitis Optica Spectrum Disorders (NMOSD) Introduction
11.5.4 Sandoz Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024)
11.5.5 Sandoz Recent Development
11.6 Intas
11.6.1 Intas Company Detail
11.6.2 Intas Business Overview
11.6.3 Intas Neuromyelitis Optica Spectrum Disorders (NMOSD) Introduction
11.6.4 Intas Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024)
11.6.5 Intas Recent Development
11.7 Nang Kuang Pharmaceutical
11.7.1 Nang Kuang Pharmaceutical Company Detail
11.7.2 Nang Kuang Pharmaceutical Business Overview
11.7.3 Nang Kuang Pharmaceutical Neuromyelitis Optica Spectrum Disorders (NMOSD) Introduction
11.7.4 Nang Kuang Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024)
11.7.5 Nang Kuang Pharmaceutical Recent Development
11.8 Tianjin King York
11.8.1 Tianjin King York Company Detail
11.8.2 Tianjin King York Business Overview
11.8.3 Tianjin King York Neuromyelitis Optica Spectrum Disorders (NMOSD) Introduction
11.8.4 Tianjin King York Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024)
11.8.5 Tianjin King York Recent Development
11.9 Baxter
11.9.1 Baxter Company Detail
11.9.2 Baxter Business Overview
11.9.3 Baxter Neuromyelitis Optica Spectrum Disorders (NMOSD) Introduction
11.9.4 Baxter Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024)
11.9.5 Baxter Recent Development
11.10 CSL
11.10.1 CSL Company Detail
11.10.2 CSL Business Overview
11.10.3 CSL Neuromyelitis Optica Spectrum Disorders (NMOSD) Introduction
11.10.4 CSL Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024)
11.10.5 CSL Recent Development
11.11 Grifols
11.11.1 Grifols Company Detail
11.11.2 Grifols Business Overview
11.11.3 Grifols Neuromyelitis Optica Spectrum Disorders (NMOSD) Introduction
11.11.4 Grifols Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024)
11.11.5 Grifols Recent Development
11.12 Octapharma
11.12.1 Octapharma Company Detail
11.12.2 Octapharma Business Overview
11.12.3 Octapharma Neuromyelitis Optica Spectrum Disorders (NMOSD) Introduction
11.12.4 Octapharma Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024)
11.12.5 Octapharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Relapsing Form
Table 3. Key Players of Monophasic Form
Table 4. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Share by Region (2019-2024)
Table 8. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Share by Region (2025-2030)
Table 10. Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Trends
Table 11. Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Drivers
Table 12. Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Challenges
Table 13. Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Restraints
Table 14. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Share by Players (2019-2024)
Table 16. Global Top Neuromyelitis Optica Spectrum Disorders (NMOSD) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) as of 2023)
Table 17. Ranking of Global Top Neuromyelitis Optica Spectrum Disorders (NMOSD) Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Neuromyelitis Optica Spectrum Disorders (NMOSD) Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Neuromyelitis Optica Spectrum Disorders (NMOSD) Product Solution and Service
Table 21. Date of Enter into Neuromyelitis Optica Spectrum Disorders (NMOSD) Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Revenue Market Share by Type (2019-2024)
Table 25. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Revenue Market Share by Type (2025-2030)
Table 27. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Revenue Market Share by Application (2019-2024)
Table 29. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Revenue Market Share by Application (2025-2030)
Table 31. North America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2025-2030) & (US$ Million)
Table 46. Roche Company Detail
Table 47. Roche Business Overview
Table 48. Roche Neuromyelitis Optica Spectrum Disorders (NMOSD) Product
Table 49. Roche Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024) & (US$ Million)
Table 50. Roche Recent Development
Table 51. Pfizer Company Detail
Table 52. Pfizer Business Overview
Table 53. Pfizer Neuromyelitis Optica Spectrum Disorders (NMOSD) Product
Table 54. Pfizer Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024) & (US$ Million)
Table 55. Pfizer Recent Development
Table 56. Fresenius Company Detail
Table 57. Fresenius Business Overview
Table 58. Fresenius Neuromyelitis Optica Spectrum Disorders (NMOSD) Product
Table 59. Fresenius Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024) & (US$ Million)
Table 60. Fresenius Recent Development
Table 61. Teva Company Detail
Table 62. Teva Business Overview
Table 63. Teva Neuromyelitis Optica Spectrum Disorders (NMOSD) Product
Table 64. Teva Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024) & (US$ Million)
Table 65. Teva Recent Development
Table 66. Sandoz Company Detail
Table 67. Sandoz Business Overview
Table 68. Sandoz Neuromyelitis Optica Spectrum Disorders (NMOSD) Product
Table 69. Sandoz Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024) & (US$ Million)
Table 70. Sandoz Recent Development
Table 71. Intas Company Detail
Table 72. Intas Business Overview
Table 73. Intas Neuromyelitis Optica Spectrum Disorders (NMOSD) Product
Table 74. Intas Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024) & (US$ Million)
Table 75. Intas Recent Development
Table 76. Nang Kuang Pharmaceutical Company Detail
Table 77. Nang Kuang Pharmaceutical Business Overview
Table 78. Nang Kuang Pharmaceutical Neuromyelitis Optica Spectrum Disorders (NMOSD) Product
Table 79. Nang Kuang Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024) & (US$ Million)
Table 80. Nang Kuang Pharmaceutical Recent Development
Table 81. Tianjin King York Company Detail
Table 82. Tianjin King York Business Overview
Table 83. Tianjin King York Neuromyelitis Optica Spectrum Disorders (NMOSD) Product
Table 84. Tianjin King York Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024) & (US$ Million)
Table 85. Tianjin King York Recent Development
Table 86. Baxter Company Detail
Table 87. Baxter Business Overview
Table 88. Baxter Neuromyelitis Optica Spectrum Disorders (NMOSD) Product
Table 89. Baxter Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024) & (US$ Million)
Table 90. Baxter Recent Development
Table 91. CSL Company Detail
Table 92. CSL Business Overview
Table 93. CSL Neuromyelitis Optica Spectrum Disorders (NMOSD) Product
Table 94. CSL Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024) & (US$ Million)
Table 95. CSL Recent Development
Table 96. Grifols Company Detail
Table 97. Grifols Business Overview
Table 98. Grifols Neuromyelitis Optica Spectrum Disorders (NMOSD) Product
Table 99. Grifols Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024) & (US$ Million)
Table 100. Grifols Recent Development
Table 101. Octapharma Company Detail
Table 102. Octapharma Business Overview
Table 103. Octapharma Neuromyelitis Optica Spectrum Disorders (NMOSD) Product
Table 104. Octapharma Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024) & (US$ Million)
Table 105. Octapharma Recent Development
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Share by Type: 2023 VS 2030
Figure 3. Relapsing Form Features
Figure 4. Monophasic Form Features
Figure 5. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Share by Application: 2023 VS 2030
Figure 7. Hospital Case Studies
Figure 8. Clinic Case Studies
Figure 9. Neuromyelitis Optica Spectrum Disorders (NMOSD) Report Years Considered
Figure 10. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 11. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Share by Region: 2023 VS 2030
Figure 13. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Share by Players in 2023
Figure 14. Global Top Neuromyelitis Optica Spectrum Disorders (NMOSD) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) as of 2023)
Figure 15. The Top 10 and 5 Players Market Share by Neuromyelitis Optica Spectrum Disorders (NMOSD) Revenue in 2023
Figure 16. North America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 17. North America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Share by Country (2019-2030)
Figure 18. United States Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. Canada Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Europe Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Share by Country (2019-2030)
Figure 22. Germany Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. France Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. U.K. Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Italy Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Russia Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Nordic Countries Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Asia-Pacific Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Share by Region (2019-2030)
Figure 30. China Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Japan Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. South Korea Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Southeast Asia Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. India Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Australia Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Latin America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Share by Country (2019-2030)
Figure 38. Mexico Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Brazil Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Middle East & Africa Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Share by Country (2019-2030)
Figure 42. Turkey Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Saudi Arabia Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Roche Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024)
Figure 45. Pfizer Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024)
Figure 46. Fresenius Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024)
Figure 47. Teva Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024)
Figure 48. Sandoz Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024)
Figure 49. Intas Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024)
Figure 50. Nang Kuang Pharmaceutical Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024)
Figure 51. Tianjin King York Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024)
Figure 52. Baxter Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024)
Figure 53. CSL Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024)
Figure 54. Grifols Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024)
Figure 55. Octapharma Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2019-2024)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
